Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Affordable Prescriptions for Patients Through Promoting Competition Act of 2021
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access; "Affordable Prescriptions for Patients Act of 2021 (S 1435 & HR.2873); Affordable Prescriptions for Patients Act of 2021 (S.1435)
Affordable Prescriptions for Patients Through Promoting Competition Act of 2021
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2025 · fourth_quarter · Q4
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil; US Tariffs
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Source: Senate LDA
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access; "Affordable Prescriptions for Patients Act of 2021 (S 1435 & HR.2873); Affordable Prescriptions for Patients Act of 2021 (S.1435)
Affordable Prescriptions for Patients Through Promoting Competition Act of 2021
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access; "Affordable Prescriptions for Patients Act of 2021 (S 1435 & HR.2873); Affordable Prescriptions for Patients Act of 2021 (S.1435)
Affordable Prescriptions for Patients Through Promoting Competition Act of 2021
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access; "Affordable Prescriptions for Patients Act of 2021 (S 1435 & HR.2873); Affordable Prescriptions for Patients Act of 2021 (S.1435)
Affordable Prescriptions for Patients Act of 2021
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access; "Affordable Prescriptions for Patients Act of 2021 (S 1435 & HR.2873); Affordable Prescriptions for Patients Act of 2021 (S.1435)
Affordable Prescriptions for Patients Act of 2021
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access; "Affordable Prescriptions for Patients Act of 2021 (S 1435 & HR.2873); Affordable Prescriptions for Patients Act of 2021 (S.1435)
Affordable Prescriptions for Patients Act of 2021
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access; "Affordable Prescriptions for Patients Act of 2021 (S 1435 & HR.2873); Affordable Prescriptions for Patients Act of 2021 (S.1435)
Affordable Prescriptions for Patients Act of 2021
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access; "Affordable Prescriptions for Patients Act of 2021 (S 1435 & HR.2873); Affordable Prescriptions for Patients Act of 2021 (S.1435)
Affordable Prescriptions for Patients Through Promoting Competition Act of 2021
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access; "Affordable Prescriptions for Patients Act of 2021 (S 1435 & HR.2873)
Affordable Prescriptions for Patients Through Promoting Competition Act of 2021
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access; "Affordable Prescriptions for Patients Act of 2021 (S 1435 & HR.2873); Affordable Prescriptions for Patients Act of 2021 (S.1435)
Affordable Prescriptions for Patients Act of 2021
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access; "Affordable Prescriptions for Patients Act of 2021 (S 1435 & HR.2873); Affordable Prescriptions for Patients Act of 2021 (S.1435)
Affordable Prescriptions for Patients Act of 2021
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access; "Affordable Prescriptions for Patients Act of 2021 (S 1435 & HR.2873)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2025 · second_quarter · 2A
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil; US Tariffs
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2025 · first_quarter · 1A
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil; US Tariffs
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2025 · third_quarter · Q3
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil; US Tariffs
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2025 · second_quarter · 2A
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil; US Tariffs
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2025 · first_quarter · 1A
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil; US Tariffs
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2025 · second_quarter · Q2
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil; US Tariffs
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2025 · first_quarter · Q1
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil; US Tariffs
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2024 · fourth_quarter · 4A
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2024 · fourth_quarter · 4A
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2024 · fourth_quarter · 4A
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2024 · fourth_quarter · Q4
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2024 · third_quarter · Q3
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2024 · second_quarter · Q2
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2024 · first_quarter · Q1
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2023 · fourth_quarter · Q4
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2023 · third_quarter · Q3
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2023 · second_quarter · 2A
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2023 · second_quarter · Q2
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2023 · first_quarter · Q1
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Saudi Arabia; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2022 · fourth_quarter · Q4
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access; "Affordable Prescriptions for Patients Act of 2021 (S 1435 & HR.2873); Affordable Prescriptions for Patients Act of 2021 (S.1435)
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Saudi Arabia; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2022 · third_quarter · Q3
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Saudi Arabia; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access; "Affordable Prescriptions for Patients Act of 2021 (S 1435 & HR.2873); Affordable Prescriptions for Patients Act of 2021 (S.1435)
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2022 · second_quarter · Q2
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Saudi Arabia; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access; "Affordable Prescriptions for Patients Act of 2021 (S 1435 & HR.2873); Affordable Prescriptions for Patients Act of 2021 (S.1435)
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2022 · first_quarter · Q1
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Saudi Arabia; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access; "Affordable Prescriptions for Patients Act of 2021 (S 1435 & HR.2873); Affordable Prescriptions for Patients Act of 2021 (S.1435)
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2021 · fourth_quarter · Q4
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Saudi Arabia; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access; "Affordable Prescriptions for Patients Act of 2021 (S 1435 & HR.2873); Affordable Prescriptions for Patients Act of 2021 (S.1435)
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2021 · third_quarter · Q3
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access; "Affordable Prescriptions for Patients Act of 2021 (S 1435 & HR.2873)
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Saudi Arabia; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-Kenta, and US-Brazil
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2021 · second_quarter · Q2
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Saudi Arabia; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-Kenta, and US-Brazil
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2021 · first_quarter · 1A
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Saudi Arabia; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-Kenta, and US-Brazil
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2021 · first_quarter · Q1
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Saudi Arabia; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-Kenta, and US-Brazil
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2020 · fourth_quarter · Q4
Issues related to intellectual property protection and market access within current trade negotiations; Canada IP; USMCA implementation; Saudi Arabia; Mexico patent linkage; Special 301; Trade talks - US-Japan, US-China, US-EU, US-UK, US-Kenya, and US-Brazil
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2020 · third_quarter · Q3
Issues related to intellectual property protection and market access within current trade negotiations; Canada IP; USMCA implementation; Saudi Arabia; Mexico patent linkage; Special 301; Trade talks - US-Japan, US-China, US-EU, US-UK, US-Kenya, and US-Brazil
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2020 · second_quarter · Q2
Issues related to intellectual property protection and market access within current trade negotiations; Canada IP; USMCA implementation; Saudi Arabia; Mexico patent linkage; Special 301; Trade talks - US-Japan, US-China, US-EU, US-UK, US-Kenya, and US-Brazil
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2020 · first_quarter · Q1
Issues related to intellectual property protection and market acccess within current trade negotiations; Turkey IPR and Pricing; Canada IP; USMCA Passage; Saudi Arabia; Mexico patent linkage; Special 301; Trade talks - US-Japan, US-China, US-EU, and US-UK
Filing targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2019 · fourth_quarter · Q4
Issues related to intellectual property protection and market acccess within current trade negotiations; Turkey IPR and Pricing; Canada IP; USMCA Passage; Saudi Arabia; Mexico patent linkage; Special 301; Trade talks - US-Japan, US-China, US-EU, and US-UK
Filing targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2019 · third_quarter · Q3
Issues related to intellectual property protection and market acccess within current trade negotiations; Turkey IPR and Pricing; Canada IP; USMCA Passage; Saudi Arabia; Thailand OCPA; Malaysia Compulsory Licenses; Special 301; Trade talks - US-Japan, US-China, US-EU, and US-UK
Filing targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2019 · second_quarter · 2A
Issues related to intellectual property protection and market acccess within current trade negotiations; Turkey IPR and Pricing; Canada IP; USMCA Passage; Saudi Arabia; Thailand OCPA; Malaysia Compulsory Licenses; Special 301; Trade talks - US-Japan, US-China, US-EU, and US-UK
Filing targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2019 · second_quarter · Q2
Issues related to intellectual property protection and market acccess within current trade negotiations; Turkey IPR and Pricing; Canada IP; USMCA Passage; Saudi Arabia; Thailand OCPA; Malaysia Compulsory Licenses; Special 301; Trade talks - US-Japan, US-China, US-EU, and US-UK
Filing targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2019 · first_quarter · Q1
Sanitary and phytosanitary issues (SPS); Japan; Turkey (country) Pricing; IPR and Pricing; Canada IP; USMCA Passage; Saudi Arabia; Thailand OCPA; Malaysia Compulsory Licenses; Special 301
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2018 · fourth_quarter · Q4
Sanitary and phytosanitary issues (SPS); Japan; Turkey (country) Pricing; IPR and Pricing; Canada IP; NAFTA renegotiation; Colombia OELD Accession; Saudi Arabia
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2018 · third_quarter · 3A
Sanitary and phytosanitary issues (SPS); Japan; Turkey (country) Pricing; IPR and Pricing; Canada IP; NAFTA renegotiation; Colombia OELD Accession
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2018 · third_quarter · Q3
Sanitary and phytosanitary issues (SPS); Japan; Turkey (country) Pricing; IPR and Pricing; Canada IP; NAFTA renegotiation; Colombia OELD Accession
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2018 · second_quarter · Q2
Sanitary and phytosanitary issues (SPS); Japan; Turkey (country) Pricing; IPR and Pricing; Canada IP; NAFTA renegotiation; Colombia OELD Accession
Filing targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)